Trabectedin is a cancer medication used to treat soft tissue sarcoma (a type of cancer that develops in soft tissues like muscles and fat). It works by interfering with cancer cell growth and division. This medication is typically used when other treatments, particularly those containing anthracyclines, have not worked effectively.

tTF-NGR is an experimental therapy designed to work together with Trabectedin. It’s a protein that targets blood vessels in tumors and is intended to help trap the cancer medication (Trabectedin) inside the tumor. This combination approach aims to make the cancer treatment more effective by keeping the medication concentrated where it’s needed most.

Soft Tissue Sarcoma – A rare type of cancer that develops in soft tissues of the body, including muscles, tendons, fat, blood vessels, nerves, and deep skin tissues. It can occur in any part of the body, though it most commonly appears in the arms, legs, and abdomen. The disease typically begins as a painless lump that grows over time. As the disease progresses, it can spread (metastasize) to other parts of the body, particularly to the lungs. Soft tissue sarcomas comprise many different subtypes, each behaving differently depending on their location and cell type of origin.

Metastatic Soft Tissue Sarcoma – An advanced stage of soft tissue sarcoma where cancer cells have spread from their original location to other parts of the body. In this stage, tumors develop in distant organs or tissues, most commonly affecting the lungs, but can also appear in the liver or bones. The disease at this stage typically manifests as multiple tumors in different body locations. The metastatic process occurs when cancer cells break away from the primary tumor and travel through the bloodstream or lymphatic system to form new tumors elsewhere.